UB

Upstream Bio, Inc.

UPB·NASDAQ

$20.97

-5.9%
HealthcareBiotechnology

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.

At a Glance

Live Snapshot
Market Cap$1.13B
EPS-0.7400
P/E Ratio-3.69
Earnings Date11/06/2025

upb

Revenue

Last Annual Value

2.37M

3-Year CAGR

25%

5-Year CAGR

14%

10-Year CAGR

7%

UB

Upstream Bio, Inc. Competitors Analysis of Revenue

UPB · NASDAQ
CompanyRevenue
CAGR 3Y
CAGR 5Y
CAGR 10Y
2.37M
-0.1%N/AN/A 
2.04M
-10.4%6.6%N/A
0.00
N/AN/AN/A
4.63M
N/AN/AN/A
15.36M
-15.6%38.4%N/A
SEPN logo
Septerna, Inc.
NASDAQ:SEPN
45.95M
572.6%N/AN/A
10.00M
-41.5%N/AN/A
0.00
N/AN/AN/A
55.23M
-15.1%-11.5%-10.4%
175.11M
535.6%N/AN/A
UB

Upstream Bio, Inc. Fair Value Envelope

UPB · NASDAQ

Our analysis suggests that UPB has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $20.97, this represents a potential HIDDEN relative to our calculated worth for Upstream Bio, Inc..

Intrinsic Value
Current Price: $20.97